Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2024-01-04 00:00:00 ET · period of report 2023-05-17 · accession 0001209191-24-000825 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMI | 2024-01-04 | 2023-05-17 | SPRY | Lowenthal Richard E | Pres, CEO, Dir, 10% | G - Gift | $0.00 | +1.05M | 1.05M | New | $0 |
| D | 2024-01-04 | 2023-05-17 | SPRY | Lowenthal Richard E | Pres, CEO, Dir, 10% | G - Gift | $0.00 | -1.05M | 4.13M | -20% | $0 |
| D | 2024-01-04 | 2024-01-02 | SPRY | Lowenthal Richard E | Pres, CEO, Dir, 10% | A - Grant | $0.00 | +880.0K | 880.0K | New | $0 |
| DI | 2024-01-04 | 2024-01-02 | SPRY | Lowenthal Richard E | Pres, CEO, Dir, 10% | A - Grant | $0.00 | +300.0K | 300.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-17 | G | A | 1,050,000 | $0.00 | 2,100,000 | I | — | — | |
| 2 | Common | Common Stock | 2023-05-17 | G | D | 1,050,000 | $0.00 | 3,276,854 | I By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 | — | — | (F1) These shares are held in a trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust. |
| 3 | Common | Common Stock | 2023-05-17 | G | A | 1,050,000 | $0.00 | 1,050,000 | I By spouse | — | — | |
| 4 | Common | Common Stock | 2023-05-17 | G | D | 1,050,000 | $0.00 | 4,126,822 | D By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 | — | — | (F1) These shares are held in a trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust. |
| 5 | Derivative | Stock option (right to buy) | 2024-01-02 | A | A | 880,000 | $0.00 | 880,000 | D By spouse | $5.58 · — to 2034-01-01 | 880,000 Common Stock | (F4) 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years. |
| 6 | Derivative | Stock option (right to buy) | 2024-01-02 | A | A | 300,000 | $0.00 | 300,000 | I | $5.58 · — to 2034-01-01 | 300,000 Common Stock | (F4) 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years. |